Brief: Biomx Reports Phase 2 Study Of Newly Selected Phage Cocktail Candidate Bx005 In Atopic Dermatitis Expected To Initiate In H2 2021

Biomx

31/03/2021 11:47

March 31 (Reuters) - Biomx Inc  PHGE.A :
    * BIOMX REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
    * BIOMX - PHASE 2 PROOF-OF-CONCEPT CLINICAL STUDY OF NEWLY
SELECTED PHAGE COCKTAIL CANDIDATE, BX005, IN ATOPIC DERMATITIS
EXPECTED TO INITIATE IN H2 2021
    * BIOMX - EXISTING CASH, CASH EQUIVALENTS, SHORT-TERM
DEPOSITS
SUFFICIENT TO FUND CURRENT OPERATING PLAN, CAPITAL EXPENDITURE
REQUIREMENTS THROUGH MID-2022

Source text for Eikon:  ID:nBw1fkzsla 
Further company coverage:  PHGE.A 

 ((Reuters.Briefs@thomsonreuters.com;))